학술논문
Barotrauma, invasive ventilation, and timing of tocilizumab as predictors of mortality along with inflammatory markers and comorbidities in critically ill COVID-19 patients: A retrospective study.
Document Type
Article
Source
Subject
*COVID-19
*SARS-CoV-2
*CRITICALLY ill
*COMORBIDITY
*COUGH
*DECOMPRESSION sickness
*
*
*
*
*
Language
ISSN
0019-5049
Abstract
NIV in properly selected patients can provide successful outcomes even in severe and critically ill COVID-19 patients. Introduction As of 12 SP th sp April 2021, the novel coronavirus disease (COVID)-19 pandemic affected 135,646,617 individuals and caused 2,930,732 deaths globally.[[1]] In most of the affected individuals, the disease is known to be of mild to moderate severity. The COVID-19 pandemic claimed many lives despite the fact that several measures including drugs such as azithromycin, favipiravir, remdesivir and 2-Deoxy-D-glucose were tried in the treatment of COVID-19 patients.[[13]],[[14]] We observed no significant difference in mortality with tocilizumab administration. [Extracted from the article]